Bionomics (Bionomics) Common Stock : $156.51 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Bionomics Common Stock?

Bionomics's quarterly common stock increased from Mar. 2023 ($0.00 Mil) to Jun. 2023 ($149.94 Mil) and increased from Jun. 2023 ($149.94 Mil) to Dec. 2023 ($156.51 Mil).

Bionomics's annual common stock increased from Jun. 2021 ($145.41 Mil) to Jun. 2022 ($152.98 Mil) but then declined from Jun. 2022 ($152.98 Mil) to Jun. 2023 ($149.94 Mil).

Bionomics Common Stock Historical Data

The historical data trend for Bionomics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionomics Common Stock Chart

Bionomics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Common Stock

Get a 7-Day Free Trial

100.66

102.25

145.41

152.98

149.94

Bionomics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Common Stock	Get a 7-Day Free Trial															-	150.81	-	149.94	156.51

Bionomics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Bionomics (Bionomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bionomics Ltd (NAS:BNOX) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

B1N0:Germany

Address

200 Greenhill Road, Eastwood, SA, AUS, 5063

Website

https://www.bionomics.com.au

Bionomics Ltd is a global, clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.